NCT06571396View on ClinicalTrials.gov

Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

April 1, 2014

Primary Completion Date

August 1, 2025

Study Completion Date

August 3, 2026

Conditions
Carcinoma, HepatocellularImmunotherapy
Trial Locations (1)

250012

RECRUITING

Qilu hospital of Shandong university, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER